Reconsider the ban: on oxytocin
The Union Health Ministry’s ban on the retail sale and private manufacture of oxytocin, expected to kick off on September 1, is an extremely ill-thought-out one. The drug, a synthetic version of a human hormone, is a life-saver for women. Doctors use it to induce labour in pregnant women and to stem postpartum bleeding. So critical is its role in maternal health that the World Health Organization recommends it as the drug of choice in postpartum haemorrhage.
The government’s ban ignores this, and is motivated instead by the misuse of the hormone in the dairy industry. Because oxytocin stimulates lactation in cattle, dairy farmers inject the drug indiscriminately to increase milk production. This has spawned several unlicensed facilities that manufacture the drug for veterinary use. It is a problem that needs solving. But the right approach would have been to strengthen regulation, and crack down on illegal production. Much is unknown about the ill-effects of oxytocin on cattle.
One of the concerns was that oxytocin leads to infertility in dairy animals, and some studies show this to be true. It has also been linked to mastitis, a painful inflammation of the udder. Milk consumers worry about exposure to it through dairy products. The science behind some of these claims is unclear. In a Lok Sabha answer in 2015, the National Dairy Research Institute was quoted as saying there was no evidence that oxytocin led to infertility. A 2014 study by researchers at the National Institute of Nutrition concluded that oxytocin content in buffalo milk did not alter with injections.
However, even if the ill-effects of oxytocin are real, a ban is not the answer. Oxytocin is simply too important to Indian women, 45,000 of whom die due to causes related to childbirth each year. A parallel to the situation lies in the misuse of antibiotics in humans and poultry. So heavily are these drugs used that they are causing deadly bacteria to become resistant to them. Yet, despite calls for a complete ban on over-the-counter sale of antibiotics, India has been reluctant to do so.
In much of rural India, more people still die due to a lack of antibiotics than due to antibiotic-resistance. This has swung the cost-benefit ratio against outright bans. In oxytocin’s case, if only a single public sector unit manufactures the drug, as the government plans, this could lead to drug shortages and price hikes. Karnataka Antibiotics & Pharmaceuticals Limited, the drugmaker tasked with manufacturing oxytocin, has been asked to cap the price at ₹16.56 for 1 ml of a five international unit (IU) solution. However, some private manufacturers were selling it for ₹4 until now. Monopolising production will remove the low-price options from the market. Such a situation may benefit cattle, but will put the lives of many women at risk.
courtesy : thehindu.com
Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.
Texas halts H-1B visas at state universities, agencies; to affect Indians
Houston (US) (PTI): Texas Governor Greg Abbott has ordered state agencies and public universities to immediately halt new H-1B visa petitions, tightening hiring rules at taxpayer-funded institutions, a step likely to impact Indian professionals.
The freeze will remain in effect through May 2027.
The directive issued on Tuesday said that the state agencies and public universities must stop filing new petitions unless they receive written approval from the Texas Workforce Commission.
The governor's order, in a red state that is home to thousands of H-1B visa holders, comes as the Trump administration has initiated steps to reshape the visa programme.
“In light of recent reports of abuse in the federal H-1B visa programme, and amid the federal government’s ongoing review of that programme to ensure American jobs are going to American workers, I am directing all state agencies to immediately freeze new H-1B visa petitions as outlined in this letter,” Abbot said.
Institutions must also report on H-1B usage, including numbers, job roles, countries of origin, and visa expiry dates, the letter said.
US President Donald Trump on September 19 last year signed a proclamation ‘Restriction on entry of certain non-immigrant workers’ that restricted the entry into the US of those workers whose H-1B petitions are not accompanied or supplemented by a payment of USD 1,00,000.
The H1-B visa fee of USD 1,00,000 would be applicable only to new applicants, i.e. all new H-1B visa petitions submitted after September 21, including those for the FY2026 lottery.
Indians make up an estimated 71 per cent of all approved H-1B applications in recent years, according to US Citizenship and Immigration Services (USCIS), with China in the second spot. The major fields include technology, engineering, medicine, and research.
Tata Consultancy Services (TCS) is the second-highest beneficiary with 5,505 approved H-1B visas in 2025, after Amazon (10,044 workers on H-1B visas), according to the USCIS. Other top beneficiaries include Microsoft (5,189), Meta (5,123), Apple (4,202), Google (4,181), Deloitte (2,353), Infosys (2,004), Wipro (1,523) and Tech Mahindra Americas (951).
Texas public universities employ hundreds of foreign faculty and researchers, many from India, across engineering, healthcare, and technology fields.
Date from Open Doors -- a comprehensive information resource on international students and scholars studying or teaching at higher education institutions in the US -- for 2022-2023 showed 2,70,000 students from India embarked on graduate and undergraduate degrees in US universities, accounting for 25 per cent of the international student population in the US and 1.5 per cent of the total student population.
Indian students infuse roughly USD 10 billion annually into universities and related businesses across the country through tuition and other expenses – while also creating around 93,000 jobs, according to the Open Doors data.
Analysts warn the freeze could slow recruitment of highly skilled professionals, affecting academic research and innovation.
Supporters say the directive protects local jobs, while critics caution it could weaken Texas’ competitiveness in higher education and research.
The order comes amid broader debate in the US over skilled immigration and state-level interventions in federal programmes.
H-1B visas allow US companies to hire technically-skilled professionals that are not easily available in America. Initially granted for three years, these can be extended for another three years.
In September 2025, Trump had also signed an executive order ‘The Gold Card’, aimed at setting up a new visa pathway for those committed to supporting the United States; with individuals who can pay USD 1 million to the US Treasury, or USD 2 million if a corporation is sponsoring them, to get access to expedited visa treatment and a path to a Green Card.
